Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FABP7 | O15540 | 2/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135438 | 0.82 | CA1 (0.44) | CA1CA2CASP3EPHX2KMT2A | |
| SCHEMBL29393453 | 0.81 | CA1 (0.53) | CA1CA2CASP3EPHX2KMT2A | |
| SCHEMBL12719 | 0.81 | CA1 (0.53) | CA1CA2CASP3EPHX2KMT2A | |
| SCHEMBL1934604 | 0.81 | CA1 (0.43) | CA1CA2CASP3EPHX2KMT2A | |
| SCHEMBL1539602 | 0.81 | CA1 (0.47) | CA1CA2CASP3EPHX2KMT2A | |
| SCHEMBL1934603 | 0.79 | KMT2A (0.43) | CA1CA2CASP3EPHX2KMT2A | |
| SCHEMBL21843101 | 0.78 | CA1 (0.42) | CA1CA2CASP3EPHX2KMT2A | |
| SCHEMBL16253852 | 0.78 | KMT2A (0.48) | CA1CA2CASP3EPHX2KMT2A | |
| Methylene Chloride SCHEMBL28181606 | 0.77 | CA1 (0.49) | CA1CA2CASP3EPHX2KMT2A | |
| SCHEMBL13270319 | 0.76 | PTPRC (0.42) | CA1CA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099917-A1 | Novel inhibitors and methods for their preparation | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099917-A1 | Novel inhibitors and methods for their preparation | TK1, ABL1, FLT3 | CA1 2277/4885CA2 2445/4885CASP3 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.